A Randomized Controlled Trial of Glycyrrhizin Plus Tenofovir vs. Tenofovir in Chronic Hepatitis B with Severe Acute Exacerbation
Open Access
- 1 June 2017
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical and Translational Gastroenterology
- Vol. 8 (6), e104
- https://doi.org/10.1038/ctg.2017.29
Abstract
Severe acute exacerbation (SAE) of chronic hepatitis B (CHB) may progress to liver failure with high potential mortality despite the prompt treatment with nucleos(t)ide analogs. This study aimed to evaluate the efficacy and safety of glycyrrhizin in the treatment of CHB with SAE. Sixty patients with SAE of CHB were randomly treated with tenofovir plus intravenous glycyrrhizin (group A, n=30) or with tenofovir alone (group B, n=30). Primary end points were the improvement of serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) and model for end-stage liver disease (MELD) score. Secondary end point was overall mortality or receipt of liver transplantation by week 24. Patients in group A had significant reductions of serum AST and ALT levels from baseline at days 3, 5, 8, and 15 than those in group B (all P<0.05). The MELD score significantly decreased since week 1 in the group A patients, whereas there were no changes relative to baseline in group B patients at weeks 1 and 2. By week 24, one (3.3%) of group A patients and four (13.3%) of group B patients died (n=3) or received liver transplantation (n=1) (P=0.177). Multivariate analysis identified baseline MELD score (P=0.021) as an independent factor for mortality or receipt of liver transplantation. There were no differences in the rates of grade 3 hypertension, hypokalemia and ascites between two groups. Early introduction of glycyrrhizin can be safe and helpful for patients with SAE of CHB.Keywords
This publication has 35 references indexed in Scilit:
- Intravenous glycyrrhizin improved serum transaminases rapidly in a chronic hepatitis B patient with acute exacerbationJournal of the Formosan Medical Association, 2015
- The Efficacy and Safety of Nucleos(t)ide Analogues in Patients with Spontaneous Acute Exacerbation of Chronic Hepatitis B: A Systematic Review and Meta-AnalysisPLOS ONE, 2013
- Granulocyte Colony–Stimulating Factor Mobilizes CD34+ Cells and Improves Survival of Patients With Acute-on-Chronic Liver FailureGastroenterology, 2012
- Glycyrrhizin in patients who failed previous interferon alpha‐based therapies: biochemical and histological effects after 52 weeksJournal of Viral Hepatitis, 2012
- Efficacy of Intravenous Glycyrrhizin in the Early Stage of Acute Onset Autoimmune HepatitisDigestive Diseases and Sciences, 2011
- Acute-on-chronic liver failure: extracorporeal liver assist devicesCurrent Opinion in Critical Care, 2011
- The Natural History of Chronic HBV Infection and Geographical DifferencesAntiviral Therapy, 2010
- Liver transplantation for acute-on-chronic liver failureHepatology International, 2009
- Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosisThe Esophagus, 2003
- Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection: Incidence, predisposing factors and etiologyJournal of Hepatology, 1990